The FY2025 (Dec) proxy of ImmunityBio names 12 peer companies for pay. Among ImmunityBio and these peers, CEO pay was 3rd highest of 7 and total shareholder return was 6th highest of 7.
3rd highest of 7in ImmunityBio and its pay peers, FY2025 (Dec) by CEO pay:
$6.9M$25.6M
6th highest of 7in ImmunityBio and its pay peers, FY2025 (Dec) by total shareholder return:
$6$148
Pay peer group, FY2025 (Dec) proxy
| TG Therapeutics | ||
| BridgeBio Pharma | ||
| Ultragenyx Pharmaceutical | ||
| Immunocore Holdings | ||
| Novavax | ||
| Neurocrine Biosciences | ||
| Allogene Therapeutics, Inc. | Not disclosed | Not disclosed |
| Arcus Biosciences, Inc. | Not disclosed | Not disclosed |
| Blueprint Medicines Corporation | Not disclosed | Not disclosed |
| Fate Therapeutics, Inc. | Not disclosed | Not disclosed |
| Kura Oncology, Inc. | Not disclosed | Not disclosed |
| Syndax Pharmaceuticals | Not disclosed | Not disclosed |
12 companies
Changes by year
FY2025 (Dec) proxy
- AddedBlueprint Medicines Corporationpay peer groupto better align with ImmunityBio’s industry, financial size
- AddedImmunocore Holdingspay peer groupto better align with ImmunityBio’s industry, financial size
- AddedTG Therapeuticspay peer groupto better align with ImmunityBio’s industry, financial size
- RemovedExact Sciences Corporationpay peer groupto better align with ImmunityBio’s industry, financial size
- RemovedMirati Therapeutics, Inc.pay peer groupto better align with ImmunityBio’s industry, financial size
- RemovedNaterapay peer groupto better align with ImmunityBio’s industry, financial size
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.